Skip to main content

Quality of Life (SNOT-22) in adults

DUPIXENT PROVIDED RAPID AND SUSTAINED QoL
IMPROVEMENT OVER TIME1,a-d

Not an actual
DUPIXENT patient.

DUPIXENT PROVIDED RAPID AND SUSTAINED QoL
IMPROVEMENT OVER TIME1,a-d

Not an actual
DUPIXENT patient.

Measured by SNOT-22, a QoL questionnaire used for CRSwNP patients1

SINUS-52

Analysis was not multiplicity controlled. Results are descriptive. Definitive conclusions cannot be made.1

aSNOT-22 score at Week 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -10.57 (95% CI: -14.47, -6.66) (-18.97 from a baseline score of 50.16 vs -8.40 from a baseline score of 53.48, respectively).1

bSNOT-22 score at Week 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -16.76 (95% CI:
-20.85, -12.67) (-27.08 from a baseline score of 50.16 vs -10.32 from a baseline score of 53.48, respectively).1

cSNOT-22 score at Week 52 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -20.96 (95% CI:
-25.03, -16.89) (-29.84 from a baseline score of 50.16 vs -8.88 from a baseline score of 53.48, respectively).1

dSNOT-22 score at Week 24 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS
(n=153): -17.36 (95% CI: -20.87, -13.85) (-27.77 from a baseline score of 51.02 vs -10.40 from a baseline score of 53.48, respectively)
(P<0.0001).1

22-item Sino-Nasal Outcome Test (SNOT-22) score (range 0-110): reduced score indicates improvement.2

CRSwNP, chronic rhinosinusitis with nasal polyps; INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks; QoL, quality of life.

Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance
treatment in adults with inadequately controlled CRSwNP.2

TURN TO DUPIXENT TO IMPROVE A RANGE OF CRSwNP SYMPTOMS
AND QoL MEASURES1

SNOT-22 MEASURES
THE QoL OF CRSwNP
PATIENTS1

The SNOT-22 score is calculated from a patient questionnaire in which 22 symptoms are rated from 0 (“no problem”) to 5 (“problem as
bad as it can be”) based on the severity and frequency of each particular item.2,3

The study was not designed to measure the impact of treatment on the individual components. Therefore, improvement in
the total aggregate SNOT-22 score does not necessarily correlate with a positive effect on each individual item or domain.3,4

Sleep

  • Difficulty falling asleep
  • Wake up at night
  • Lack of a good night's sleep

Function

  • Wake up tired
  • Fatigue
  • Reduced productivity
  • Reduced concentration

Ear/Facial

  • Ear fullness
  • Dizziness
  • Ear pain
  • Facial pain/pressure

Emotional

  • Frustrated
    /restless
    /irritable
  • Sad
  • Embarrassed

Nasal

  • Need to blow nose
  • Nasal blockage
  • Sneezing
  • Runny nose
  • Cough
  • Postnasal discharge
  • Thick nasal discharge
  • Decreased sense of smell/taste

Explore the Safety Data, Study Designs, and Dosage and Administration

Explore SAFETY DATA AND STUDY DESIGNS
Explore dosage and administration